Impact BioMedical (IBO) S-1/A 30 Jun 23 IPO registration (amended) Financial data

Cover

Cover	3 Months Ended
	Mar. 31, 2023
Entity Addresses [Line Items]
Document Type	S-1/A
Amendment Flag	true
Amendment Description	Amendment No. 12
Entity Registrant Name	IMPACT BIOMEDICAL INC.
Entity Central Index Key	0001834105
Entity Tax Identification Number	85-3926944
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	275 Wiregrass Pkwy
Entity Address, City or Town	West Henrietta
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14586
City Area Code	+1
Local Phone Number	585-325-3610
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	Impact BioMedical Inc.
Entity Address, Address Line Two	275 Wiregrass Pkwy
Entity Address, City or Town	West Henrietta
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14586
City Area Code	+1
Local Phone Number	585-325-3610
Contact Personnel Name	Frank D. Heuszel

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,000	$ 2,000	$ 46,000
Current portion of notes receivable	205,000	16,000	197,000
Prepaid expenses and other current assets	183,000	104,000	44,000
Total current assets	389,000	122,000	287,000
Property, plant and equipment, net	279,000	276,000
Other investments	782,000	782,000	4,817,000
Notes receivable		190,000	5,081,000
Goodwill	25,093,000	25,093,000	25,093,000
Other intangible assets, net	19,756,000	20,034,000	21,147,000
Total assets	46,299,000	46,497,000	56,425,000
Current liabilities:
Accounts payable	186,000	539,000	115,000
Accrued expenses	50,000	63,000	6,000
Note payable, related party	$ 11,008,000	$ 9,529,000	12,524,000
Notes Payable, Current, Related and Nonrelated Party Status [Extensible Enumeration]	Related Party [Member]	Related Party [Member]
Total current liabilities	$ 11,244,000	$ 10,131,000	12,645,000
Deferred tax liability, net	3,235,000	3,235,000	3,856,000
Total liabilities	14,479,000	13,366,000	16,501,000
Commitments and contingencies (Note 12)
Stockholder’s equity
Common stock, $.001 par value; 3,000,000,000 shares authorized, 125,073,621 shares issued and outstanding (125,073,621 on March 31, 2023 and December 31, 2022)	125,000	125,000	125,000
Additional paid-in capital	38,058,000	38,058,000	38,058,000
Accumulated deficit	(9,282,000)	(8,625,000)	(1,574,000)
Total stockholder’s equity of the company	28,901,000	29,558,000	36,609,000
Non-controlling interest in subsidiary	2,919,000	3,111,000	3,315,000
Total stockholder’s equity	31,820,000	32,669,000	39,924,000
Total liabilities and stockholder’s equity	$ 46,299,000	46,497,000	56,425,000
Previously Reported [Member]
Current assets:
Cash and cash equivalents		2,000
Current portion of notes receivable		16,000
Prepaid expenses and other current assets		104,000
Total current assets		122,000
Property, plant and equipment, net		276,000
Other investments		782,000
Notes receivable		190,000
Goodwill		25,093,000
Other intangible assets, net		20,034,000
Total assets		46,497,000
Current liabilities:
Accounts payable		539,000
Accrued expenses		63,000
Note payable, related party		9,991,000
Total current liabilities		10,593,000
Deferred tax liability, net		3,235,000
Total liabilities		13,828,000
Commitments and contingencies (Note 12)
Stockholder’s equity
Common stock, $.001 par value; 3,000,000,000 shares authorized, 125,073,621 shares issued and outstanding (125,073,621 on March 31, 2023 and December 31, 2022)		125,000
Additional paid-in capital		38,058,000
Accumulated deficit		(8,625,000)
Total stockholder’s equity of the company		29,558,000
Non-controlling interest in subsidiary		3,111,000
Total stockholder’s equity		32,669,000	$ 39,924,000
Total liabilities and stockholder’s equity		$ 46,497,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2022 $ / shares shares
Common stock, par value | $ / shares	$ 0.001
Common stock, shares authorized	3,000,000,000
Common stock, shares issued	125,073,621
Common stock, shares outstanding	125,073,621
Previously Reported [Member]
Common stock, par value | $ / shares	$ 0.001
Common stock, shares authorized	4,000,000,000
Common stock, shares issued	3,877,282,251
Common stock, shares outstanding	3,877,282,251

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Costs and expenses:
Selling, general and administrative compensation	$ 40,000	$ 123,000		$ 398,000
Research & development	179,000	168,000	$ 1,226,000	1,080,000
Professional services	280,000	126,000		552,000
Depreciation and amortization	280,000	278,000	1,113,000	1,113,000
Other general expense	40,000	14,000		42,000
Total costs and expenses	819,000	709,000		3,185,000
Operating loss	(819,000)	(709,000)		(3,185,000)
Other income (expense):
Interest income	3,000	96,000		165,000
Other income (expense)	68,000			77,000
Interest expense	(101,000)	(133,000)		(300,000)
Impairment of investment
Loss from continuing operations	(849,000)	(746,000)		(3,243,000)
Income tax (loss)/benefit			621,000	1,395,000
Net loss	(849,000)	(746,000)		(1,848,000)
Loss from continuing operations attributed to noncontrolling interest	192,000	77,000		545,000
Net loss attributable to common stockholders	$ (657,000)	$ (669,000)		$ (1,303,000)
Loss per common share:
Basic	$ 0	$ (0.01)		$ 0
Diluted
Shares used in computing loss per common share:
Basic	3,877,282,251	3,877,282,251		3,877,282,251
Diluted	3,877,282,251	3,877,282,251		3,877,282,251
Income tax benefit			(621,000)	$ (1,395,000)
Previously Reported [Member]
Costs and expenses:
Selling, general and administrative compensation			325,000
Research & development			1,226,000
Professional services			722,000
Depreciation and amortization			1,113,000
Other general expense			68,000
Total costs and expenses			3,454,000
Operating loss			(3,454,000)
Other income (expense):
Interest income			24,000
Other income (expense)			116,000
Interest expense			(462,000)
Impairment of investment			(4,100,000)
Loss from continuing operations			(7,876,000)
Income tax (loss)/benefit			621,000
Net loss			(7,255,000)	$ (1,848,000)
Loss from continuing operations attributed to noncontrolling interest			204,000
Net loss attributable to common stockholders			$ (7,051,000)
Loss per common share:
Basic			$ 0
Diluted
Shares used in computing loss per common share:
Basic			3,877,282,251
Diluted			3,877,282,251
Income tax benefit			$ (621,000)

Consolidated Statements of Stoc

Consolidated Statements of Stockholder's Equity - USD ($)	Common Stock [Member] Previously Reported [Member]	Common Stock [Member]	Additional Paid-in Capital [Member] Previously Reported [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member] Previously Reported [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member] Previously Reported [Member]	Noncontrolling Interest [Member]	Previously Reported [Member]	Total
Balance at Dec. 31, 2020		$ 125,000		$ 38,058,000		$ (271,000)		$ 3,860,000		$ 41,772,000
Balance, shares at Dec. 31, 2020		3,877,282,251
Net loss					$ (1,303,000)		$ (545,000)		$ (1,848,000)	(1,848,000)
Issuance of common stock, net
Proceeds from shareholder
Balance at Dec. 31, 2021	$ 125,000	$ 125,000	38,058,000	38,058,000	(1,574,000)	(1,574,000)	(3,315,000)	3,315,000	39,924,000	39,924,000
Balance, shares at Dec. 31, 2021	3,877,282,251	3,877,282,251
Net loss						(669,000)		(77,000)		(746,000)
Balance at Mar. 31, 2022		$ 125,000		38,058,000		(2,243,000)		3,238,000		39,178,000
Balance, shares at Mar. 31, 2022		3,877,282,251
Balance at Dec. 31, 2021	$ 125,000	$ 125,000	38,058,000	38,058,000	(1,574,000)	(1,574,000)	(3,315,000)	3,315,000	39,924,000	39,924,000
Balance, shares at Dec. 31, 2021	3,877,282,251	3,877,282,251
Net loss					(7,051,000)		(204,000)		(7,255,000)
Balance at Dec. 31, 2022	$ 125,000	$ 125,000	$ 38,058,000	38,058,000	$ (8,625,000)	(8,625,000)	$ 3,111,000	3,111,000	$ 32,669,000	32,669,000
Balance, shares at Dec. 31, 2022		3,877,282,251
Net loss						(657,000)		(192,000)		(849,000)
Balance at Mar. 31, 2023		$ 125,000		$ 38,058,000		$ (9,282,000)		$ 2,919,000		$ 31,820,000
Balance, shares at Mar. 31, 2023		3,877,282,251

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (849,000)	$ (746,000)		$ (1,848,000)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization	280,000	278,000	$ 1,113,000	1,113,000
Deferred tax benefit				(1,395,000)
Impairment of other investments
Decrease (increase) in assets:
Prepaid expenses and other current assets	(79,000)	(37,000)		(8,000)
Deferred Tax benefit
Impairment of other investment
Increase (decrease) in liabilities:
Accounts payable	(353,000)	(60,000)		106,000
Accrued expenses	(13,000)	32,000		5,000
Net cash used by operating activities	(1,014,000)	(533,000)		(2,027,000)
Cash flows from investing activities:
Purchase of property, plant and equipment	(5,000)
Purchase of investment		(12,000)		(4,185,000)
Note receivable investment, net	1,000	(93,000)		(5,278,000)
Net cash used by investing activities	(4,000)	(105,000)		(9,463,000)
Cash flows from financing activities:
Borrowings from note payable, related party	1,017,000	625,000		11,464,000
Net cash provided by financing activities	1,017,000	625,000		11,464,000
Net decrease in cash	(1,000)	(13,000)		(27,000)
Cash and cash equivalents at beginning of period	2,000	46,000	46,000	72,000
Cash and cash equivalents at end of period	1,000	33,000	2,000	46,000
Previously Reported [Member]
Cash flows from operating activities:
Net loss			(7,255,000)	(1,848,000)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization			1,113,000
Deferred tax benefit			(621,000)
Impairment of other investments			4,100,000
Decrease (increase) in assets:
Prepaid expenses and other current assets			(60,000)
Increase (decrease) in liabilities:
Accounts payable			424,000
Accrued expenses			57,000
Net cash used by operating activities			(2,242,000)
Cash flows from investing activities:
Purchase of property, plant and equipment			(276,000)
Purchase of investment			(65,000)
Note receivable investment, net			(8,000)
Net cash used by investing activities			(349,000)
Cash flows from financing activities:
Borrowings from note payable, related party			2,547,000
Net cash provided by financing activities			2,547,000
Net decrease in cash			(44,000)
Cash and cash equivalents at beginning of period	$ 2,000	$ 46,000	46,000
Cash and cash equivalents at end of period			$ 2,000	$ 46,000

Nature of Operations and Basis

Nature of Operations and Basis of Presentation	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Basis of Presentation	Note 1. Nature of Operations and Basis of Presentation Nature of Operations Impact BioMedical, Inc. (the “Company”, “Impact BioMedical”, “We”) through the utilization of its intellectual property rights, or through investment in, or through acquisition of companies in the biohealth and biomedical fields, focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Global BioLife, Inc. (“Global BioLife”), one of the Company’s subsidiaries and the main operating company of the group, focuses on research in four main areas: (i) the “Linebacker” project, which aims to develop a universal therapeutic drug platform; (ii) a new sugar substitute called “Laetose,”; (iii) a multi-use fragrance called “3F” (Functional Fragrance Formulation); and (iv) Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication. Linebacker Unlike the traditional approach to treat individual diseases with specific drugs, the Linebacker platform seeks to offer a breakthrough therapeutic option for multiple diseases. Linebacker is designed to work by inhibiting a cascade of inflammatory responses responsible for many diseases. Its design is in direct contrast to the traditional approach of targeting individual diseases with specific drugs. Laetose We have also developed a low-calorie, low glycemic level, natural modified sugar through Global BioLife. The product, “Laetose,” is designed to possess low glycemic properties and mitigate inflammation. The Company is presently seeking to license Laetose. Global BioLife established a joint venture, Sweet Sense, Inc. (“Sweet Sense”), with Quality Ingredients, LLC for the development, manufacture, and global distribution of the new sugar substitute. On November 8, 2019, the Company purchased 50 91,000 81.8 Functional Fragrance Formulation (“3F”) Global BioLife has established a collaboration with U.S.-based Chemia Corporation (“Chemia”) to develop specialized fragrances to counter mosquito-borne diseases such as Zika and Dengue, among other medical applications. The 3F mosquito fragrance product is made from specialized oils sourced from botanicals that mosquitos avoid. Global BioLife is seeking to commercialize this product. Together with Chemia, we are attempting to license 3F. Any potential profits from the 3F project will be split between Global BioLife and Chemia pursuant to the terms of the 20- year Royalty Agreement (Note 11). Equivir Equivir, is a polyphenol compound that is believed to be successful in antiviral infection treatments. Equivir is a patented medication, that has broad antiviral efficacy against multiple types of infectious disease. The Company was incorporated in the State of Nevada as a for-profit company on October 16, 2018 and established a fiscal year end of December 31st. The Company issued 9,000 125,064,621 As of the date of this report, we have not generated significant revenues from operations. We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including possible delays in our research, testing and marketing efforts or wider economic downturns. Basis of Presentation and Principles of Consolidation The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements include all accounts of the Company and its majority owned and controlled subsidiaries. The Company consolidates entities in which it owns more than 50 IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements The consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting periods as follows: Schedule of Condensed Financial Statements Name of consolidated subsidiary State or other jurisdiction of incorporation or organization Date of incorporation or formation Attributable interest as of Attributable Global BioMedical, Inc. Nevada April 18, 2017 90.9 % 90.9 % Global BioLife, Inc. Nevada April 14, 2017 81.8 % 81.8 % BioLife Sugar, Inc Nevada April 23, 2018 90.9 % 90.9 % Happy Sugar Inc Nevada August 17, 2018 81.8 % 81.8 % Sweet Sense Inc. Nevada April 30, 2018 95.5 % 95.5 % Global Sugar Solutions Inc. Nevada November 7, 2019 100 % 100 % As of March 31, 2023, and December 31, 2022, the aggregate noncontrolling interest was equity of $ 2,919,000 3,111,000	Note 1. Nature of Operations and Basis of Presentation Nature of Operations Impact BioMedical, Inc. (the “Company”, “Impact BioMedical”, “We”) through the utilization of its intellectual property rights, or through investment in, or through acquisition of companies in the biohealth and biomedical fields, focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Global BioLife, Inc. (“Global BioLife”), one of the Company’s subsidiaries and the main operating company of the group, focuses on research in four main areas: (i) the “Linebacker” project, which aims to develop a universal therapeutic drug platform; (ii) a new sugar substitute called “Laetose,”; (iii) a multi-use fragrance called “3F” (Functional Fragrance Formulation); and (iv) Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication. Linebacker Unlike the traditional approach to treat individual diseases with specific drugs, the Linebacker platform seeks to offer a breakthrough therapeutic option for multiple diseases. Linebacker is designed to work by inhibiting a cascade of inflammatory responses responsible for many diseases. Its design is in direct contrast to the traditional approach of targeting individual diseases with specific drugs. Laetose We have also developed a low-calorie, low glycemic level, natural modified sugar through Global BioLife. The product, “Laetose,” is designed to possess low glycemic properties and mitigate inflammation. The Company is presently seeking to license Laetose. Global BioLife established a joint venture, Sweet Sense, Inc. (“Sweet Sense”), with Quality Ingredients, LLC for the development, manufacture, and global distribution of the new sugar substitute. On November 8, 2019, the Company purchased 50 91,000 81.8 Functional Fragrance Formulation (“3F”) Global BioLife has established a collaboration with U.S.-based Chemia Corporation (“Chemia”) to develop specialized fragrances to counter mosquito-borne diseases such as Zika and Dengue, among other medical applications. The 3F mosquito fragrance product is made from specialized oils sourced from botanicals that mosquitos avoid. Global BioLife is seeking to commercialize this product. Together with Chemia, we are attempting to license 3F. Any potential profits from the 3F project will be split between Global BioLife and Chemia pursuant to the terms of the 20- year Royalty Agreement (Note 12). Equivir Equivir, is a polyphenol compound that is believed to be successful in antiviral infection treatments. Equivir is a patented medication, that has broad antiviral efficacy against multiple types of infectious disease. The Company was incorporated in the State of Nevada as a for-profit company on October 16, 2018 and established a fiscal year end of December 31st. The Company issued 9,000 125,064,621 As of the date of this report, we have not generated significant revenues from operations. We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including possible delays in our research, testing and marketing efforts or wider economic downturns. Basis of Presentation and Principles of Consolidation The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements include all accounts of the Company and its majority owned and controlled subsidiaries. The Company consolidates entities in which it owns more than 50 IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements The consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting periods as follows: Schedule of Condensed Financial Statements Name of consolidated subsidiary State or other jurisdiction of incorporation or organization Date of incorporation or formation Attributable interest as of Attributable Global BioMedical, Inc. Nevada April 18, 2017 90.9 % 90.9 % Global BioLife, Inc. Nevada April 14, 2017 81.8 % 63.6 % BioLife Sugar, Inc Nevada April 23, 2018 90.9 % 63.6 % Happy Sugar Inc Nevada August 17, 2018 81.8 % 63.6 % Sweet Sense Inc. Nevada April 30, 2018 95.5 % 81.8 % Global Sugar Solutions Inc. Nevada November 7, 2019 100 % 80 % As of December 31, 2022, and 2021, the aggregate noncontrolling interest was equity of $ 3,111,000 3,315,000

Summary of Significant Accounti

Summary of Significant Accounting and Reporting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting and Reporting Policies	Note 2. Summary of Significant Accounting and Reporting Policies Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Earnings (Loss) per Share Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed like basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments issued or outstanding for the three months ended March 31, 2023 or 2022. Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company’s investments are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its carrying value as the stated interest rate reflects recent market conditions. IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements Cash and cash equivalents The Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents. There were no Investments Investments in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities, with unrealized gains and losses included in earnings. For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further discussion on investments. Goodwill Goodwill is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired. FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working capital, and growth rates. Cash flow projections are derived from one year budgeted amounts plus an estimate of later period cash flows, all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. No Intangible Assets The estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives. Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of December 31 st No Recoverability of Long-Lived Assets We evaluate long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever events or circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable. Factors that we consider include whether there has been a significant decrease in the market value of an asset, a significant change in the way an asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change in the macroeconomic environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets involves significant judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions hypothetical marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include, among others, forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total estimated future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment loss is measured and recognized. Our impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset fair values, and estimating asset’s useful lives. The Company reviews identifiable amortizable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition. Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in a non-cash impairment in future periods. Research and Development Research and development costs are expensed as incurred. Total research and development costs were $ 179,000 168,000 IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements Recent Accounting Standards The Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements, as applicable, has been or will be adopted by the Company. As of March 31, 2023, none of these pronouncements is expected to have a material effect on the financial position, results of operations or cash flows of the Company. On January 1, 2022, the Company adopted amended accounting guidance “ ASU No.2016-13 – Credit Losses” Continuing Operations and Going Concern Due to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should we be unable to continue as a going concern. To continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through March 31, 2024, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were available to be issued. The Company’s management intends to take actions necessary to continue as a going concern. Management’s plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.	Note 2. Summary of Significant Accounting and Reporting Policies Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Earnings (Loss) per Share Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed like basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments issued or outstanding for the years ended December 31, 2022 or 2021. Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company’s investments are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its carrying value as the stated interest rate reflects recent market conditions. IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements Cash and cash equivalents The Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents. There were no Investments Investments in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities, with unrealized gains and losses included in earnings. For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 7 for further discussion on investments. Goodwill Goodwill is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired. FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working capital, and growth rates. Cash flow projections are derived from one year budgeted amounts plus an estimate of later period cash flows, all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. No Intangible Assets The estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives. Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of December 31 st No impairment was recognized during the years ended December 31, 2022 or 2021. Recoverability of Long-Lived Assets We evaluate long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever events or circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable. Factors that we consider include whether there has been a significant decrease in the market value of an asset, a significant change in the way an asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change in the macroeconomic environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets involves significant judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions hypothetical marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include, among others, forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total estimated future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment loss is measured and recognized. Our impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset fair values, and estimating asset’s useful lives. The Company reviews identifiable amortizable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition. Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in a non-cash impairment in future periods. Research and Development Research and development costs are expensed as incurred. Total research and development costs were $ 1,226,000 1,080,000 IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements Recent Accounting Standards The Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements, as applicable, has been or will be adopted by the Company. As of December 31, 2022, none of these pronouncements is expected to have a material effect on the financial position, results of operations or cash flows of the Company. Continuing Operations and Going Concern Due to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should we be unable to continue as a going concern. To continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through December 31, 2022, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were available to be issued. The Company’s management intends to take actions necessary to continue as a going concern. Management’s plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.

Restatement

Restatement	12 Months Ended
	Dec. 31, 2022
Accounting Changes and Error Corrections [Abstract]
Restatement	Note 3. Restatement The Company has determined that a restatement of the December 31, 2022 consolidated financial statements is appropriate in order to correct certain errors in the reporting of interest expense on the related party note. In previously issued consolidated financial statements, there was no interest expense recorded. Interest expense has been corrected and restated from $ 0 462,000

Prepaid Expenses

Prepaid Expenses	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Prepaid Expenses
Prepaid Expenses	Note 3. Prepaid Expenses Prepaid expenses for the three months ended March 31, 2023, includes prepaid inventory approximating $ 140,000 and research and development fees paid to GRDG Sciences, LLC. (“GRDG”), a related party, approximating $ 43,000 . Prepaid expenses at December 31, 2022 of $ 104,000 including research and development costs to GRDG approximating $ 43,000 .	Note 4. Prepaid Expenses Prepaid expenses for the year ended December 31, 2022, includes prepared inventory approximating $ 60,000 43,000 43,000

Notes Receivable

Notes Receivable	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Receivables [Abstract]
Notes Receivable	Note 4. Notes Receivable On February 21, 2021, Impact BioMedical, Inc. entered into a promissory note (“Promissory Note 1”) with an individual. The Company loaned the principal sum of $ 206,000 6.5 August 19, 2022 August 19, 2023 205,000 206,000 205,000 205,000	Note 5. Notes Receivable On February 21, 2021, Impact BioMedical, Inc. entered into a promissory note (“Promissory Note 1”) with an individual. The Company loaned the principal sum of $ 206,000 6.5 August 19, 2022 August 19, 2023 206,000 197,000 206,000 16,000 190,000 On May 14, 2021, DSS PureAir, Inc. (“DSS PureAir”), a wholly owned subsidiary of the Company, entered into a convertible promissory note (“Promissory Note 2”) with a limited liability company registered in the state of Texas (“Borrower”). The Promissory Note 2 has an aggregate principal balance up to $ 5,000,000 6.5 May 14, 2023 18 100 0 5,081,000

Investments

Investments	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Investments, All Other Investments [Abstract]
Investments	Note 5. Investments On December 19, 2020, Impact BioMedical entered into a subscription agreement (the “Subscription Agreement”) with BioMed Technologies Asia Pacific Holdings Limited (“BioMed”), a limited liability company incorporated in the British Virgin Islands, pursuant to which the Company agreed to purchase 525 4.99 632,000 BioMed focuses on manufacturing natural probiotics, pursuant to which the Company will directly market, advertise, promote, distribute and sell certain BioMed products to resellers. The products to be distributed by the Company include BioMed’s PGut Premium Probiotics ® ® ® ® ® Effective January 1, 2021, the Company entered into a securities purchase agreement (“SPA”) with Nano9, LLC. (“Nano9”), a Utah limited partnership. For the consideration of $ 150,000 1,000 10 150,000 IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements On March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the “Vivacitas Agreement #1”) with Vivacitas Oncology Inc. (“Vivacitas”), to purchase 500,000 1.00 1,500,000 1.00 This option will terminate upon one of the following events: (i) Vivacitas’ board of directors cancels this option because it is no longer in the best interest of the Company; (ii) December 31, 2022; or (iii) the date on which Vivacitas receives more than $1.00 per share of the Company’s common stock in a private placement with gross proceeds of $ 500,000 2,480,000 2,480,000 250,000 On April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $ 1.00 120,000 On July 22, 2021, the Company exercised 1,000,000 1,000,000 4,035,000 100 4,100,000	Note 6. Investments On December 19, 2020, Impact BioMedical entered into a subscription agreement (the “Subscription Agreement”) with BioMed Technologies Asia Pacific Holdings Limited (“BioMed”), a limited liability company incorporated in the British Virgin Islands, pursuant to which the Company agreed to purchase 525 4.99 632,000 BioMed focuses on manufacturing natural probiotics, pursuant to which the Company will directly market, advertise, promote, distribute and sell certain BioMed products to resellers. The products to be distributed by the Company include BioMed’s PGut Premium Probiotics ® ® ® ® ® Effective January 1, 2021, the Company entered into a securities purchase agreement (“SPA”) with Nano9, LLC. (“Nano9”), a Utah limited partnership. For the consideration of $ 150,000 1,000 10 150,000 IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements On March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the “Vivacitas Agreement #1”) with Vivacitas Oncology Inc. (“Vivacitas”), to purchase 500,000 1.00 1,500,000 1.00 This option will terminate upon one of the following events: (i) Vivacitas’ board of directors cancels this option because it is no longer in the best interest of the Company; (ii) December 31, 2022; or (iii) the date on which Vivacitas receives more than $1.00 per share of the Company’s common stock in a private placement with gross proceeds of $ 500,000 2,480,000 2,480,000 250,000 On April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $ 1.00 120,000 On July 22, 2021, the Company exercised 1,000,000 1,000,000 4,035,000 100 4,100,000

PROPERTY PLANT AND EQUIPMENT an

PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET	Note 6. PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET Property, plant and equipment consisted of the following as of: Schedule of Property Plant and Equipment Estimated March 31, December 31, Useful Life 2023 2022 Machinery and equipment 5 10 $ 30,000 $ 25,000 Construction in progress 251,000 251,000 Total Cost 281,000 276,000 Property, plant and equipment, gross 281,000 276,000 Less accumulated depreciation 2,000 - Property, plant and equipment, net $ 279,000 $ 276,000 Depreciation expense for the three months ended March 31, 2023 and 2022 was $ 2,000 0	Note 7. PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET Property, plant and equipment consisted of the following as of December 31, 2022: Schedule of Property Plant and Equipment Estimated Useful Life 2022 2021 Machinery and equipment 5 10 $ 25,000 $ - Construction in progress 251,000 - Total Cost 276,000 - Property, plant and equipment, gross 276,000 - Less accumulated depreciation - - Property, plant and equipment, net $ 276,000 $ - Depreciation expense for the years ended December 31, 2022 and 2021 was $ - -

Goodwill

Goodwill	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Note 7. Goodwill Goodwill balances and activity for the three months ended March 31, 2023 and year ended December 31, 2022 consisted of the following: Schedule of Goodwill Balance at December 31, 2022 $ 25,093,000 Goodwill adjustment - Balance at March 31, 2023 $ 25,093,000 During 2022, management performed annual goodwill impairment testing. No goodwill impairment was identified as a result of these tests. As of June 1, 2022 a quantitative analysis was prepared utilizing the Market Approach and Income Approach valuing the Company.	Note 8. Goodwill Goodwill balances and activity for the year ended December 31, 2022 and year ended December 31, 2021 consisted of the following: Schedule of Goodwill Balance at December 31, 2021 $ 25,093,000 Goodwill adjustment - Balance at December 31, 2022 $ 25,093,000 During 2022 and 2021, management performed annual goodwill impairment testing. No goodwill impairment was identified as a result of these tests. As of June 1, 2022 a quantitative analysis was prepared utilizing the Market Approach and Income Approach valuing the Company. The guideline public company Market Approach produced a mean business enterprise value indication using estimated 2025 results of $69.24 million. The Income Approach was based upon the use of a discounted pro forma cash flow model and produced a business enterprise value indication of $56.54 million. A weighting of 20% to the weighted value indicated was applied under the Market Approach, a weighting of 10% to the prior transaction value and a weighting of 70% to the value indicated under the Income Approach. A lower weighting was applied to the Market Approach due to the fact of using forecasted earnings of the Company. Based upon the above weightings, an initial value of $57.26 million for Impact was calculated. Adding cash and cash equivalents of $ 33,000 13.15 44.14 4.9 12.5 During 2021, we used qualitative factors to determine whether it was more likely than not (likelihood of more than 50%) that the fair value of a reporting unit exceeded its carrying amount.

Intangible Assets

Intangible Assets	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 8. Intangible Assets The definite-lived intangible assets, to be amortized over 20 years, balances, and activity for the three months Schedule of Intangible Assets 03/31/2023 12/31/2022 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Definitive-lived: Developed technology 22,258,000 $ (2,502,000 ) $ 19,756,000 $ 22,258,000 $ (2,226,000 ) $ 20,033,000 Total 22,258,000 $ (2,502,000 ) $ 19,756,000 $ 22,258,000 $ (2,226,000 ) $ 20,033,000 Amounts amortized for the three months ended March 31, 2023 and 2022 was approximately $ 280,000 278,000 The following table represents future amortization of developed technologies for the years ending December 31: Schedule of Future Amortization of Developed Technologies 2023 $ 835,000 2024 $ 1,113,000 2025 $ 1,113,000 2026 $ 1,113,000 2027 $ 1,113,000 Thereafter $ 14,469,000 IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements An impairment analysis was conducted for financial reporting purposes in connection with U.S. GAAP and ASC 360-10, Impairment and Disposal of Long-Lived Assets. Although the Company has a history of negative cash flows from operations, its financing arrangement with DSS (see Note 9) provides the opportunity to fund ongoing operations. This, as well as there being no other indicators present for impairment, has led management to conclude that no impairment is necessary for the three months ended March 31, 2023, and 2022.	Note 9. Intangible Assets The definite-lived intangible assets, to be amortized over 20 years, balances and activity for the years ended December 31, 2022, and 2021 consisted of the following: Schedule of Intangible Assets 12/31/2022 12/31/2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Definitive-lived: Developed technology 22,258,000 $ (2,226,000 ) $ 20,033,000 $ 22,260,000 $ (1,113,000 ) $ 21,147,000 Total 22,258,000 $ (2,226,000 ) $ 20,033,000 $ 22,260,000 $ (1,113,000 ) $ 21,147,000 Amounts amortized for the year ended December 31, 2022 and 2021 was approximately $ 1,113,000 1,113,000 The following table represents future amortization of developed technologies: Schedule of Future Amortization of Developed Technologies 2022 $ 1,113,000 2023 $ 1,113,000 2024 $ 1,113,000 2025 $ 1,113,000 2026 $ 1,113,000 Thereafter $ 14,468,000 IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements In March 2021, the fair value of the assets acquired by DSS on August 21, 2020, was concluded. An impairment analysis was conducted for financial reporting purposes in connection with U.S. GAAP and ASC 360-10, Impairment and Disposal of Long-Lived Assets. Although the Company has a history of negative cash flows from operations, its financing arrangement with DSS (see Note 9) provides the opportunity to fund ongoing operations. This, as well as there being no other indicators present for impairment, has led management to conclude that no impairment is necessary for the years ended December 31, 2022, and 2021.

Debt

Debt	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Debt	Note 9. Debt On December 31, 2020, and later amended on March 31, 2023, the Company executed a Revolving Promissory Note (“Note”) with DSS, a related party, which accrues interest at a rate of 4.25 % and is due in full at the maturity date of March 31, 2024 . The revolving nature of this Note permits for principal amounts borrowed to be repaid and reborrowed. In the case of default, at DSS’s option, (i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its sole discretion may choose to charge; but never more than the Maximum Lawful Rate. DSS has not established a maximum borrowing amount and intends to continue to fund the operations of the Company through a year from the date these financial statements were available to be issued. As of March 31, 2023 and December 31, 2022, this Note has an outstanding balance, including interest of $ 11,008,000 and 9,529,000 respectively.	Note 10. Debt On December 31, 2020, and later amended on December 31, 2022, the Company executed a Revolving Promissory Note (“Note”) with DSS, a related party, which accrues interest at a rate of 4.25 December 31, 2023 In the case of default, at DSS’s option, (i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its sole discretion may choose to charge; but never more than the Maximum Lawful Rate. 9,991,000 12,524,000

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Stockholders’ Equity	Note 10. Stockholders’ Equity On September 23, 2021, the Company, the Company’s Board of Directors approved the total number of shares of Common Stock to be 3,000,000,000 0.001 4,000,000,000 0.001 100,000,000 0.001 125,073,621 no 3,877,282,251 no	Note 11. Stockholders’ Equity On September 23, 2021, the Company, the Company’s Board of Directors approved the total number of shares of Common Stock to be 3,000,000,000 0.001 Our Amended and Restated Articles of Incorporation authorizes us to issue up to 4,000,000,000 0.001 100,000,000 0.001 3,877,282,251 no 125,073,621 3,877,282,251 no

Related Party Transactions

Related Party Transactions	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 11. Related Party Transactions Research and Development Activities Based on Shareholders Agreement entered into on April 26, 2017, the Company would fund the scientific operations of GRDG, a company involved in research and development of biomedical products which is a minority stockholder of two of the Company’s subsidiaries and is owned by Daryl Thompson, a director of many subsidiaries of the Company, to do the development and research works on the biomedical products for the Company. As of March 31, 2023, this funding approximates $ 43,000 129,000 0 43,000 43,000 General and Administrative Costs There are certain general and administrative costs incurred by DSS, a related party on behalf of the Company which are passed through to the Company on a monthly basis. These costs consist of primarily payroll costs for certain DSS employees and are allocated based on estimated time spent on behalf of the Company. These costs approximate $ 12,000 35,000 52,000 IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements	Note 12. Related Party Transactions Research and Development Activities Based on Shareholders Agreement entered into on April 26, 2017, the Company would fund the scientific operations of GRDG, a company involved in research and development of biomedical products which is a minority stockholder of two of the Company’s subsidiaries and is owned by Daryl Thompson, a director of many subsidiaries of the Company, to do the development and research works on the biomedical products for the Company. As of December 31, 2022, this funding approximates $ 43,000 546,000 0 43,000 43,000 General and Administrative Costs There are certain general and administrative costs incurred by DSS, a related party on behalf of the Company which are passed through to the Company on a monthly basis. These costs consist of primarily payroll costs for certain DSS employees and are allocated based on estimated time spent on behalf of the Company. These costs approximate $ 12,000 117,000 155,000 IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 12. Commitments and Contingencies On August 15, 2018, the Company entered into Royalty Agreement with Chemia Corporation (“Chemia”) pursuant to which Chemia transferred to the Company all of its right to 3F (Functional Fragrance Formulation). This agreement has a 20-year term and auto renews for a period of 1 year unless mutually agreed upon by both parties. 3F consists of 3F Mosquito Repellant and 3F Anti-Viral formulations. Based on the Royalty Agreement, the Company should cover all the costs to prepare and finalize necessary patent application and other intellectual property related to 3F. Chemia agreed to support the Company in efforts leading to development of 3F intellectual property and it’s licensing. Based on Royalty Agreement any payments received from development, sales, licensing or transfer of 3F technology will be paid 50 50 5 On February 15, 2022, the Company and its subsidiaries, Global BioLife, Inc. (“Global”), and Impact BioLife Sciences, Inc. (“BioLife Sciences”), and GRDG entered into a Licensing Proceeds Distribution Agreement (“GRDG Agreement”), whereas GRDG would transfer its 20 On March 19, 2022, Impact BioMedical entered into a License Agreement (“Equivir License”) with ProPhase Labs, Inc. (“ProPhase”) where the ProPhase is granted the right, amongst other things, to develop, commercialize, and sell the Company’s Equivir technology. In exchange, the Licensee shall pay the Company a royalty of 5.5 50 1,250,000	Note 13. Commitments and Contingencies On August 15, 2018, the Company entered into Royalty Agreement with Chemia Corporation (“Chemia”) pursuant to which Chemia transferred to the Company all of its right to 3F (Functional Fragrance Formulation). This agreement has a 20-year term and auto renews for a period of 1 year unless mutually agreed upon by both parties. 3F consists of 3F Mosquito Repellant and 3F Anti-Viral formulations. Based on the Royalty Agreement, the Company should cover all the costs to prepare and finalize necessary patent application and other intellectual property related to 3F. Chemia agreed to support the Company in efforts leading to development of 3F intellectual property and it’s licensing. Based on Royalty Agreement any payments received from development, sales, licensing or transfer of 3F technology will be paid 50 50 5 On February 15, 2022, the Company and its subsidiaries, Global BioLife, Inc. (“Global”), and Impact BioLife Sciences, Inc. (“BioLife Sciences”), and GRDG entered into a Licensing Proceeds Distribution Agreement (“GRDG Agreement”), whereas GRDG would transfer its 20 On March 19, 2022, Impact BioMedical entered into a License Agreement (“Equivir License”) with ProPhase Labs, Inc. (“ProPhase”) where the ProPhase is granted the right, amongst other things, to develop, commercialize, and sell the Company’s Equivir technology. In exchange, the Licensee shall pay the Company a royalty of 5.5 50 1,250,000

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 14. Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities. Deferred tax assets are reduced, if deemed necessary, by a valuation allowance for the amount of tax benefits which are not expected to be realized. IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements The components of income tax benefit for the years ended December 31, 2022, and 2021 are as follows: Schedule of Components of Income Tax Benefit Federal $ - $ - Income Tax Expense (Benefit) Year Ended Year Ended December 31, 2021 Current tax payable Federal $ - $ - State - - Total current tax payable - - Deferred tax Federal (1,619,000 ) (456,000 ) State (165,000 ) (1,068,000 ) Total deferred tax $ (1,784,000 ) $ (1,524,000 ) Less increase in valuation allowance 1,163,000 129,000 Total income tax benefit $ (621,000 ) $ (1,395,000 ) Individual components of deferred tax assets and liabilities are approximately as follows: Schedule of Deferred Tax Assets and Liabilities - - Deferred Tax Assets & Liabilities: Deferred Tax assets: Impairment of investment $ 929,000 $ - Research & development cost 250,000 - Net Operating loss 1,611,000 1,258,000 Gross deferred tax assets 2,790,000 1,258,000 Deferred tax liability: Intangible assets (4,414,000 ) (4,667,000 ) Gross deferred tax liability (4,414,000 ) (4,667,000 ) Less valuation allowance (1,611,000 ) (447,000 ) Net deferred tax liability $ (3,235,000 ) $ (3,856,000 ) Summary of Effective Income Tax Rate 2022 2021 Statutory United States federal rate 21.0 % 21.0 % State income taxes net of federal benefit 1.7 % 26.0 % Change in valuation allowance (14.8 )% (4.0 )% Effective rate 7.9 % 43 % As of December 31, 2022, and 2021, the Company has net operating loss carry forwards of approximately $ 7,109,000 5,551,000 2,790,000 1,258,000 1,163,000 129,000 The Company recognizes interest accrued and penalties related to unrecognized tax benefits in tax expense. During the years ended December 31, 2022 and 2021 the Company recognized no interest and penalties.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	Note 15. Supplemental Cash Flow Information The following table summarizes supplemental cash flows for the year ended December 31, 2022, and 2021: Schedule of Cash Flow Supplemental 2022 2021 Transfer of promissory note 2 to related party $ 5,081,000 $ - Transfer of note payable, related party $ (5,081,000 ) $ -

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 13. Subsequent Events The Company has evaluated all subsequent events and transactions through June 20, 2023, the date that the consolidated financial statements were available to be issued and noted no subsequent events requiring financial statement recognition or disclosure.	Note 16. Subsequent Events The Company has evaluated all subsequent events and transactions through June 2, 2023, the date that the consolidated financial statements were available to be issued, and noted no subsequent events requiring financial statement recognition or disclosure.

Summary of Significant Accoun_2

Summary of Significant Accounting and Reporting Policies (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Use of estimates	Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.	Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.
Earnings (Loss) per Share	Earnings (Loss) per Share Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed like basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments issued or outstanding for the three months ended March 31, 2023 or 2022.	Earnings (Loss) per Share Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed like basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments issued or outstanding for the years ended December 31, 2022 or 2021.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company’s investments are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its carrying value as the stated interest rate reflects recent market conditions. IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company’s investments are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its carrying value as the stated interest rate reflects recent market conditions. IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents. There were no	Cash and cash equivalents The Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents. There were no
Investments	Investments Investments in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities, with unrealized gains and losses included in earnings. For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further discussion on investments.	Investments Investments in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities, with unrealized gains and losses included in earnings. For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 7 for further discussion on investments.
Goodwill	Goodwill Goodwill is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired. FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working capital, and growth rates. Cash flow projections are derived from one year budgeted amounts plus an estimate of later period cash flows, all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. No	Goodwill Goodwill is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired. FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working capital, and growth rates. Cash flow projections are derived from one year budgeted amounts plus an estimate of later period cash flows, all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. No
Intangible Assets	Intangible Assets The estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives. Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of December 31 st No	Intangible Assets The estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives. Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of December 31 st No impairment was recognized during the years ended December 31, 2022 or 2021.
Recoverability of Long-Lived Assets	Recoverability of Long-Lived Assets We evaluate long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever events or circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable. Factors that we consider include whether there has been a significant decrease in the market value of an asset, a significant change in the way an asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change in the macroeconomic environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets involves significant judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions hypothetical marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include, among others, forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total estimated future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment loss is measured and recognized. Our impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset fair values, and estimating asset’s useful lives. The Company reviews identifiable amortizable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition. Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in a non-cash impairment in future periods.	Recoverability of Long-Lived Assets We evaluate long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever events or circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable. Factors that we consider include whether there has been a significant decrease in the market value of an asset, a significant change in the way an asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change in the macroeconomic environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets involves significant judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions hypothetical marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include, among others, forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total estimated future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment loss is measured and recognized. Our impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset fair values, and estimating asset’s useful lives. The Company reviews identifiable amortizable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition. Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in a non-cash impairment in future periods.
Research and Development	Research and Development Research and development costs are expensed as incurred. Total research and development costs were $ 179,000 168,000 IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements	Research and Development Research and development costs are expensed as incurred. Total research and development costs were $ 1,226,000 1,080,000 IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements
Recent Accounting Standards	Recent Accounting Standards The Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements, as applicable, has been or will be adopted by the Company. As of March 31, 2023, none of these pronouncements is expected to have a material effect on the financial position, results of operations or cash flows of the Company. On January 1, 2022, the Company adopted amended accounting guidance “ ASU No.2016-13 – Credit Losses”	Recent Accounting Standards The Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements, as applicable, has been or will be adopted by the Company. As of December 31, 2022, none of these pronouncements is expected to have a material effect on the financial position, results of operations or cash flows of the Company.
Continuing Operations and Going Concern	Continuing Operations and Going Concern Due to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should we be unable to continue as a going concern. To continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through March 31, 2024, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were available to be issued. The Company’s management intends to take actions necessary to continue as a going concern. Management’s plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.	Continuing Operations and Going Concern Due to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should we be unable to continue as a going concern. To continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through December 31, 2022, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were available to be issued. The Company’s management intends to take actions necessary to continue as a going concern. Management’s plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.

Nature of Operations and Basi_2

Nature of Operations and Basis of Presentation (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Condensed Financial Statements	The consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting periods as follows: Schedule of Condensed Financial Statements Name of consolidated subsidiary State or other jurisdiction of incorporation or organization Date of incorporation or formation Attributable interest as of Attributable Global BioMedical, Inc. Nevada April 18, 2017 90.9 % 90.9 % Global BioLife, Inc. Nevada April 14, 2017 81.8 % 81.8 % BioLife Sugar, Inc Nevada April 23, 2018 90.9 % 90.9 % Happy Sugar Inc Nevada August 17, 2018 81.8 % 81.8 % Sweet Sense Inc. Nevada April 30, 2018 95.5 % 95.5 % Global Sugar Solutions Inc. Nevada November 7, 2019 100 % 100 %	The consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting periods as follows: Schedule of Condensed Financial Statements Name of consolidated subsidiary State or other jurisdiction of incorporation or organization Date of incorporation or formation Attributable interest as of Attributable Global BioMedical, Inc. Nevada April 18, 2017 90.9 % 90.9 % Global BioLife, Inc. Nevada April 14, 2017 81.8 % 63.6 % BioLife Sugar, Inc Nevada April 23, 2018 90.9 % 63.6 % Happy Sugar Inc Nevada August 17, 2018 81.8 % 63.6 % Sweet Sense Inc. Nevada April 30, 2018 95.5 % 81.8 % Global Sugar Solutions Inc. Nevada November 7, 2019 100 % 80 %

PROPERTY PLANT AND EQUIPMENT _2

PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property Plant and Equipment	Property, plant and equipment consisted of the following as of: Schedule of Property Plant and Equipment Estimated March 31, December 31, Useful Life 2023 2022 Machinery and equipment 5 10 $ 30,000 $ 25,000 Construction in progress 251,000 251,000 Total Cost 281,000 276,000 Property, plant and equipment, gross 281,000 276,000 Less accumulated depreciation 2,000 - Property, plant and equipment, net $ 279,000 $ 276,000	Property, plant and equipment consisted of the following as of December 31, 2022: Schedule of Property Plant and Equipment Estimated Useful Life 2022 2021 Machinery and equipment 5 10 $ 25,000 $ - Construction in progress 251,000 - Total Cost 276,000 - Property, plant and equipment, gross 276,000 - Less accumulated depreciation - - Property, plant and equipment, net $ 276,000 $ -

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill balances and activity for the three months ended March 31, 2023 and year ended December 31, 2022 consisted of the following: Schedule of Goodwill Balance at December 31, 2022 $ 25,093,000 Goodwill adjustment - Balance at March 31, 2023 $ 25,093,000	Goodwill balances and activity for the year ended December 31, 2022 and year ended December 31, 2021 consisted of the following: Schedule of Goodwill Balance at December 31, 2021 $ 25,093,000 Goodwill adjustment - Balance at December 31, 2022 $ 25,093,000

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Schedule of Intangible Assets 03/31/2023 12/31/2022 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Definitive-lived: Developed technology 22,258,000 $ (2,502,000 ) $ 19,756,000 $ 22,258,000 $ (2,226,000 ) $ 20,033,000 Total 22,258,000 $ (2,502,000 ) $ 19,756,000 $ 22,258,000 $ (2,226,000 ) $ 20,033,000	Schedule of Intangible Assets 12/31/2022 12/31/2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Definitive-lived: Developed technology 22,258,000 $ (2,226,000 ) $ 20,033,000 $ 22,260,000 $ (1,113,000 ) $ 21,147,000 Total 22,258,000 $ (2,226,000 ) $ 20,033,000 $ 22,260,000 $ (1,113,000 ) $ 21,147,000
Schedule of Future Amortization of Developed Technologies	The following table represents future amortization of developed technologies for the years ending December 31: Schedule of Future Amortization of Developed Technologies 2023 $ 835,000 2024 $ 1,113,000 2025 $ 1,113,000 2026 $ 1,113,000 2027 $ 1,113,000 Thereafter $ 14,469,000	The following table represents future amortization of developed technologies: Schedule of Future Amortization of Developed Technologies 2022 $ 1,113,000 2023 $ 1,113,000 2024 $ 1,113,000 2025 $ 1,113,000 2026 $ 1,113,000 Thereafter $ 14,468,000

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Benefit	The components of income tax benefit for the years ended December 31, 2022, and 2021 are as follows: Schedule of Components of Income Tax Benefit Federal $ - $ - Income Tax Expense (Benefit) Year Ended Year Ended December 31, 2021 Current tax payable Federal $ - $ - State - - Total current tax payable - - Deferred tax Federal (1,619,000 ) (456,000 ) State (165,000 ) (1,068,000 ) Total deferred tax $ (1,784,000 ) $ (1,524,000 ) Less increase in valuation allowance 1,163,000 129,000 Total income tax benefit $ (621,000 ) $ (1,395,000 )
Schedule of Deferred Tax Assets and Liabilities	Individual components of deferred tax assets and liabilities are approximately as follows: Schedule of Deferred Tax Assets and Liabilities - - Deferred Tax Assets & Liabilities: Deferred Tax assets: Impairment of investment $ 929,000 $ - Research & development cost 250,000 - Net Operating loss 1,611,000 1,258,000 Gross deferred tax assets 2,790,000 1,258,000 Deferred tax liability: Intangible assets (4,414,000 ) (4,667,000 ) Gross deferred tax liability (4,414,000 ) (4,667,000 ) Less valuation allowance (1,611,000 ) (447,000 ) Net deferred tax liability $ (3,235,000 ) $ (3,856,000 )
Summary of Effective Income Tax Rate	Summary of Effective Income Tax Rate 2022 2021 Statutory United States federal rate 21.0 % 21.0 % State income taxes net of federal benefit 1.7 % 26.0 % Change in valuation allowance (14.8 )% (4.0 )% Effective rate 7.9 % 43 %

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow Supplemental	The following table summarizes supplemental cash flows for the year ended December 31, 2022, and 2021: Schedule of Cash Flow Supplemental 2022 2021 Transfer of promissory note 2 to related party $ 5,081,000 $ - Transfer of note payable, related party $ (5,081,000 ) $ -

Schedule of Condensed Financial

Schedule of Condensed Financial Statements (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Global Bio Medical Inc [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
State or other jurisdiction of incorporation or organization	Nevada	Nevada
Date of incorporation or formation	Apr. 18, 2017	Apr. 18, 2017
Attributable interest percentage	90.90%	90.90%	90.90%
Global Bio Life Inc [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
State or other jurisdiction of incorporation or organization	Nevada	Nevada
Date of incorporation or formation	Apr. 14, 2017	Apr. 14, 2017
Attributable interest percentage	81.80%	81.80%	63.60%
Bio Life Sugar Inc [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
State or other jurisdiction of incorporation or organization	Nevada	Nevada
Date of incorporation or formation	Apr. 23, 2018	Apr. 23, 2018
Attributable interest percentage	90.90%	90.90%	63.60%
Happy Sugar Inc [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
State or other jurisdiction of incorporation or organization	Nevada	Nevada
Date of incorporation or formation	Aug. 17, 2018	Aug. 17, 2018
Attributable interest percentage	81.80%	81.80%	63.60%
Sweet Sense Inc [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
State or other jurisdiction of incorporation or organization	Nevada	Nevada
Date of incorporation or formation	Apr. 30, 2018	Apr. 30, 2018
Attributable interest percentage	95.50%	95.50%	81.80%
Global Sugar Solutions Inc [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
State or other jurisdiction of incorporation or organization	Nevada	Nevada
Date of incorporation or formation	Nov. 07, 2019	Nov. 07, 2019
Attributable interest percentage	100%	100%	80%

Nature of Operations and Basi_3

Nature of Operations and Basis of Presentation (Details Narrative) - USD ($)	Mar. 31, 2020	Nov. 08, 2019	Oct. 16, 2018	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Noncontrolling interest				$ 2,919,000	$ 3,111,000	$ 3,315,000
Subsidiaries [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Noncontrolling interest				$ 2,919,000	$ 3,111,000
Global Bio Medical Pte Ltd [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Stock issued during period shares	125,064,621		9,000
Sweet Sense [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Minority interest ownership percentage		50%		50%	50%
Consideration given for purchase		$ 91,000
Ownership percentage		81.80%

Summary of Significant Accoun_3

Summary of Significant Accounting and Reporting Policies (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash	$ 0		$ 0	$ 0
Impairment of goodwill
Impairment of intangible assets	0		0	0
Research and development cost	$ 179,000	$ 168,000	$ 1,226,000	$ 1,080,000

Restatement (Details Narrative)

Restatement (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Interest expense	$ 101,000	$ 133,000		$ 300,000
Minimum [Member]
Interest expense			$ 0
Maximum [Member]
Interest expense			$ 462,000

Prepaid Expenses (Details Narra

Prepaid Expenses (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Research and development	$ 179,000	$ 168,000	$ 1,226,000	$ 1,080,000
Prepaid expenses	183,000		104,000	44,000
GRDG Science LLC [Member]
Defined Benefit Plan Disclosure [Line Items]
Research and development	129,000		546,000
GRDG Science LLC [Member] | Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Prepaid expenses includes prepaid inventory	140,000		60,000
Research and development	$ 43,000	$ 43,000	43,000
Prepaid expenses			$ 104,000	$ 43,000

Notes Receivable (Details Narra

Notes Receivable (Details Narrative) - USD ($)				3 Months Ended	12 Months Ended
	Aug. 22, 2022	May 14, 2021	Feb. 21, 2021	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jun. 01, 2022
Financing Receivable, Modified [Line Items]
Note receivable principal			$ 206,000	$ 205,000
Debt stated percentage			6.50%				12.50%
Maturity date	Aug. 19, 2023		Aug. 19, 2022
Debt principal and interest				205,000	$ 206,000
Notes receivable current					205,000
Notes and loans receivable					190,000	$ 5,081,000
Debt face amount				$ 11,008,000	9,529,000
Promissory Note One [Member]
Financing Receivable, Modified [Line Items]
Note receivable principal			$ 206,000		206,000
Debt stated percentage			6.50%
Maturity date	Aug. 19, 2023		Aug. 19, 2022
Debt principal and interest					206,000	197,000
Notes receivable current					16,000
Notes and loans receivable					190,000
Promissory Note Two [Member]
Financing Receivable, Modified [Line Items]
Debt stated percentage		6.50%
Maturity date		May 14, 2023
Notes and loans receivable					$ 0	$ 5,081,000
Debt face amount		$ 5,000,000
Promissory Note Two [Member] | Maximum [Member]
Financing Receivable, Modified [Line Items]
Debt stated percentage		18%					100%

Investments (Details Narrative)

Investments (Details Narrative) - USD ($)						12 Months Ended
	Jul. 22, 2021	Mar. 18, 2021	Mar. 15, 2021	Jan. 01, 2021	Dec. 19, 2020	Mar. 31, 2022	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 23, 2021	Apr. 01, 2021
Common stock par value							$ 0.001	$ 0.001	$ 0.001	$ 0.001
Securities Purchase Agreement [Member] | Nano9 LLC [Member]
Equitable ownership percentage				10%
Stock Purchase Agreement [Member] | Common Stock [Member]
Options to purchase common stock		250,000
Stock Purchase Agreement [Member] | Impact Oncology PTE Ltd [Member]
Purchase price		$ 2,480,000
Number of common stock owned		2,480,000
Vivacitas Agreement [Member]
Investment owned at fair value									$ 4,035,000
Stock option exercised, shares	1,000,000
Stock option exercised, value	$ 1,000,000
Investment cost, percent								100%
Investment cost								$ 4,100,000
Asia Pacific Holdings Limited [Member] | Subscription Arrangement [Member]
Ordinary shares to purchase					525
Ordinary shares percentage					4.99%
Purchase price of shares					$ 632,000
Nano9 LLC [Member] | Securities Purchase Agreement [Member]
Number of shares issued, value				$ 150,000
Number of shares issued				1,000
Investment owned at fair value							$ 150,000	$ 150,000	$ 150,000
Vivacitas Oncology Inc [Member] | Stock Purchase Agreement [Member]
Number of shares issued			500,000
Common stock par value			$ 1
Options to purchase common stock			1,500,000
Share price			$ 1								$ 1
Option termination, description			This option will terminate upon one of the following events: (i) Vivacitas’ board of directors cancels this option because it is no longer in the best interest of the Company; (ii) December 31, 2022; or (iii) the date on which Vivacitas receives more than $1.00 per share of the Company’s common stock in a private placement with gross proceeds of $500,000. Under the terms of the Vivacitas Agreement #1, the Company will be allocated two seats on the board of Vivacitas
Proceeds from private placement			$ 500,000
Proceeds from issuance of common stock						$ 120,000

Schedule of Property Plant and

Schedule of Property Plant and Equipment (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 281,000	$ 276,000
Less accumulated depreciation	2,000
Property, plant and equipment, net	279,000	276,000
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 30,000	$ 25,000
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years	5 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years	10 years
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 251,000	$ 251,000

PROPERTY PLANT AND EQUIPMENT _3

PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2,000	$ 0

Schedule of Goodwill (Details)

Schedule of Goodwill (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Balance at December 31, 2022	$ 25,093,000	$ 25,093,000	$ 25,093,000
Goodwill adjustment
Balance at March 31, 2023	$ 25,093,000		$ 25,093,000	$ 25,093,000

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 22,258,000	$ 22,258,000	$ 22,260,000
Accumulated Amortization	(2,502,000)	(2,226,000)	(1,113,000)
Net Carrying Amount	19,756,000	20,033,000	21,147,000
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	22,258,000	22,258,000	22,260,000
Accumulated Amortization	(2,502,000)	(2,226,000)	(1,113,000)
Net Carrying Amount	$ 19,756,000	$ 20,033,000	$ 21,147,000

Goodwill (Details Narrative)

Goodwill (Details Narrative) - USD ($)		3 Months Ended
	Jun. 01, 2022	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Feb. 21, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Acquisition value of asset acquired, description		The guideline public company Market Approach produced a mean business enterprise value indication using estimated 2025 results of $69.24 million. The Income Approach was based upon the use of a discounted pro forma cash flow model and produced a business enterprise value indication of $56.54 million. A weighting of 20% to the weighted value indicated was applied under the Market Approach, a weighting of 10% to the prior transaction value and a weighting of 70% to the value indicated under the Income Approach. A lower weighting was applied to the Market Approach due to the fact of using forecasted earnings of the Company. Based upon the above weightings, an initial value of $57.26 million for Impact was calculated. Adding cash and cash equivalents of $33,000 to the initial business enterprise value produced a concluded business enterprise value of $57.29 million (rounded) for Impact.
Cash	$ 33,000	$ 1,000	$ 2,000	$ 46,000
Long term debt fair value	13,150,000
Equity fair value	44,140,000
Debt carrying amount	$ 4,900,000
Debt interest rate	12.50%				6.50%

Schedule of Future Amortization

Schedule of Future Amortization of Developed Technologies (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 1,113,000	$ 1,113,000
2025	1,113,000	1,113,000
2026	1,113,000	1,113,000
2027	1,113,000	1,113,000
2026		1,113,000
Thereafter	14,469,000	$ 14,468,000
2023	$ 835,000

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization	$ 280,000	$ 278,000	$ 1,113,000	$ 1,113,000

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)			3 Months Ended	12 Months Ended
	Aug. 22, 2022	Feb. 21, 2021	Mar. 31, 2023	Dec. 31, 2022	Jun. 01, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Debt instrument interest, rate		6.50%			12.50%
Debt instrument, maturity date	Aug. 19, 2023	Aug. 19, 2022
Outstanding balance				$ 9,991,000		$ 12,524,000
Outstanding balance, including interest			$ 11,008,000	$ 9,529,000
Revolving Promissory Note [Member]
Short-Term Debt [Line Items]
Debt instrument interest, rate			4.25%	4.25%
Debt instrument, maturity date			Mar. 31, 2024	Dec. 31, 2023
Long term debt, description			In the case of default, at DSS’s option, (i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its sole discretion may choose to charge; but never more than the Maximum Lawful Rate.	In the case of default, at DSS’s option, (i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its sole discretion may choose to charge; but never more than the Maximum Lawful Rate.

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - $ / shares	May 11, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 23, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Common stock, shares authorized		3,000,000,000	3,000,000,000	4,000,000,000	4,000,000,000
Common stock par value		$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized					100,000,000
Preferred stock, par value					$ 0.001
Common stock, shares issued		125,073,621	125,073,621	3,877,282,251
Common stock, shares outstanding		125,073,621	125,073,621	3,877,282,251
Subsequent Event [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Common stock, shares authorized	3,877,282,251
Preferred stock, shares issued	0		0	0
Preferred stock, shares outstanding	0
Board of Directors Chairman [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Common stock, shares authorized		4,000,000,000			3,000,000,000
Common stock par value		$ 0.001			$ 0.001
Preferred stock, shares authorized		100,000,000
Preferred stock, par value		$ 0.001
Preferred stock, shares issued			0
Preferred stock, shares outstanding			0
Common stock, shares issued			125,073,621
Common stock, shares outstanding			125,073,621

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Research & development	$ 179,000	$ 168,000	$ 1,226,000	$ 1,080,000
Related party owed transaction	0	0	0	0
Prepaid monthly fees	43,000	43,000	43,000	43,000
Related costs for employees	12,000		12,000
Related Party [Member]
Related Party Transaction [Line Items]
General and administrative expense	35,000	52,000	117,000	$ 155,000
GRDG Science LLC [Member]
Related Party Transaction [Line Items]
Payment in funding of research and development	43,000		43,000
Research & development	129,000		546,000
GRDG Science LLC [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Research & development	$ 43,000	$ 43,000	$ 43,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)						3 Months Ended
	Mar. 19, 2022	Mar. 19, 2022	Feb. 15, 2022	Nov. 27, 2018	Aug. 15, 2018	Mar. 31, 2023
Royalty Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage					50%
Sale of royalty percentage			20%	5%
Development cost, percent	50%
Royalty Agreement [Member] | Chemia Corporation [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage					50%	50%
License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of royalty percentage	5.50%
Development cost, percent		50%
Development costs	$ 1,250,000
Global And Bio Life Sciences [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of royalty percentage			20%

Schedule of Components of Incom

Schedule of Components of Income Tax Benefit (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Federal
State
Total current tax payable
Federal			(1,619,000)	(456,000)
State			(165,000)	(1,068,000)
Total deferred tax			(1,784,000)	(1,524,000)
Less increase in valuation allowance			1,163,000	129,000
Total income tax benefit			$ (621,000)	$ (1,395,000)

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Impairment of investment	$ 929,000
Research & development cost	250,000
Net Operating loss	1,611,000	1,258,000
Gross deferred tax assets	2,790,000	1,258,000
Intangible assets	(4,414,000)	(4,667,000)
Gross deferred tax liability	(4,414,000)	(4,667,000)
Less valuation allowance	(1,611,000)	(447,000)
Net deferred tax liability	$ (3,235,000)	$ (3,856,000)

Summary of Effective Income Tax

Summary of Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Statutory United States federal rate	21%	21%
State income taxes net of federal benefit	1.70%	26%
Change in valuation allowance	(14.80%)	(4.00%)
Effective rate	7.90%	43%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 7,109,000	$ 5,551,000
Deferred tax asset	2,790,000	1,258,000
Valuation allowance deferred tax	$ 1,163,000	$ 129,000

Schedule of Cash Flow Supplemen

Schedule of Cash Flow Supplemental (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Transfer of note payable, related party	$ (9,991,000)	$ (12,524,000)
Related Party [Member]
Related Party Transaction [Line Items]
Transfer of promissory note 2 to related party	5,081,000
Transfer of note payable, related party	$ (5,081,000)